肿瘤浸润淋巴细胞治疗胃癌的研究进展  

Research progress on tumor infiltrating lymphocytes for the treatment of gastric cancer

作　　者：江蜜 陈锦皇 舒晓刚 Jiang Mi;Chen Jinhuang;Shu Xiaogang(Department of Gastrointestinal Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Department of Emergency Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院胃肠外科,武汉430022 [2]华中科技大学同济医学院附属协和医院急诊外科,武汉430022

出　　处：《中华实验外科杂志》2024年第12期2682-2686,共5页Chinese Journal of Experimental Surgery

摘　　要：胃癌是全球范围内常见的恶性肿瘤之一, 其发病率和死亡率均较高。传统的胃癌治疗方法包括手术、化疗和放疗等在治疗效果上存在一定的局限性, 尤其是对于晚期或转移性胃癌患者, 治疗效果往往不佳。肿瘤浸润淋巴细胞(TIL)疗法是一种新型细胞免疫疗法, 通过利用患者自身的免疫细胞来攻击肿瘤细胞, 展现出了较强的特异性和安全性。因此, 深入探究和明确TIL治疗胃癌的机制与疗效具有重要的基础研究意义和临床应用价值, 本文将综述TIL治疗胃癌的研究进展, 并对其进行述评。Gastric cancer is one of the most common malignant tumors in the world,with a high incidence rate and mortality.The traditional treatment methods for gastric cancer,including surgery,chemotherapy,and radiation therapy,have certain limitations in terms of treatment effectiveness,especially for patients with advanced or metastatic gastric cancer.Tumor-infiltrating lymphocyte(TIL)therapy is a novel cellular immunotherapy that utilizes the patient’s own immune cells to attack tumor cells,demonstrating strong specificity and safety.Therefore,in-depth exploration and clarification of the mechanism and efficacy of TIL treatment for gastric cancer have important basic research significance and clinical application value.This article will review the research progress of TIL treatment for gastric cancer and provide a commentary on it.

关 键 词：肿瘤浸润淋巴细胞 胃癌 

分 类 号：R735.2[医药卫生—肿瘤]